Changes of macrophage inflammatory protein of efficacy of zoledronic acid therapy of multiple mye-loma and determination in serum
- VernacularTitle:唑来膦酸治疗多发性骨髓瘤骨病疗效判定及血清中巨噬细胞炎症蛋白变化
- Author:
Yunlong TANG
;
Yan ZHOU
;
Chunbin WANG
;
Naitong SUN
;
Xiaoyan YANG
;
Yu SHAO
;
Xueyun SHAN
;
Mo ZHOU
;
Weiwei SHENG
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Zoledronic acid;
Macrophage inflammatory protein
- From:
Journal of Chinese Physician
2016;(z1):9-11
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study of zoledronic acid in the treatment of multiple myeloma bone dis-ease clinical effect and detection of serum macrophage inflammatory protein (MIP)changes of primary mye-loma (mm)in patients with serum macrophage inflammatory protein levels and multiple myeloma bone dis-ease curative effect.Methods 48 cases of multiple myeloma bone disease patients were treated with VTD regimen chemotherapy were randomly and equally divided into two groups,one group (group A)chemother-apy intermission applied zoledronic acid 4 mg per month 1 time,treatment 2 course of treatment,observa-tion of curative effect and adverse reaction,another group (B group)declined to azole phosphonic acid treatment.Results Group of pain Solution of 16 cases were markedly effective,effective in 4 cases,4 ca-ses were ineffective,efficiency 83.3%.B group bone pain relieved markedly effective in 12 cases,effective in 4 cases,8 cases were ineffective,have efficiency 66.7%.A compared to the B,the curative effect was obvious (P <0.05).By enzyme linked immunosorbent assay for the detection of the patients with a,levels of peripheral serum MIP-1a and MIP-1 beta B two groups before and after treatment.Conclusions zole-dronic acid in the treatment of multiple myeloma bone disease effectively,can significantly improve the qual-ity of life in patients with MM patients serum MIP-1a and MIP-1 beta level and multiple myeloma tumor bone disease curative effect is negative correlation,used for evaluating the effect The reference index.
